Passion for Innovation. Compassion for Patients.™



Top Management Presentation Financial Results of FY2017 Q3 (April 1 – December 31, 2017)

DAIICHI SANKYO CO., LTD

Kazunori Hirokawa

Executive Vice President and CFO

January 31, 2018

Forward-Looking Statements



Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information

Agenda



- FY2017 Q3 Financial Results
- FY2017 Revised Consolidated Forecast
- 🔶 Edoxaban (Lixiana)

R&D Update

- Appendix
 - R&D Milestone Events
 - Major R&D Pipeline
 - Out-licensing Projects
 - Edoxaban (Lixiana)
 - Injectafer
 - Abbreviations



FY2017 Q3 Financial Results

Overview of FY2017 Q3 Results




	FY2016 Q3 YTD Results	FY2017 Q3 YTD Results	YoY
Revenue	734.4	741.0	+0.9% +6.6
Cost of Sales	241.7	255.5	+13.7
SG&A Expenses	220.5	216.7	-3.7
R&D Expenses	143.5	175.6	+32.1
Operating Profit	128.7	93.2	-27.6% -35.5
Profit before Tax	132.4	97.7	-34.7
Profit attributable to owners of the Company	88.2	72.6	<u>-17.7%</u> - 15.6
Currency USD/JPY	106.68	111.71	+5.03
Rate EUR/JPY	118.09	128.53	+10.44

Revenue



Increased by 6.6 Bn JPY (Decreased by 7.7 Bn JPY excl. forex impact)



^{*} Forex impact USD: +6.6, EUR : +4.7, ASCA: +3.0

Operating Profit




Decreased by 35.5 Bn JPY

(Decreased by 23.9 Bn JPY excl. forex impact and special items)

FY2016 Results	128.7	Revenue	+6.6		
Revenue	6.6	incl. forex impact	+14.3		
Cost of Sales	16.1	Cost of Sales + Product mix due to	-16.1 impact of	olmesartan	LOE
SG&A Expenses	1.5	Cost of Sales	-12.4 +3.7		
R&D Expenses	1.3	SG&A Expenses R&D Expenses	+5.4 +3.3		
Forex Impact	12.4	Special Items	FY2016 Q3 YTD Results	FY2017 Q3 YTD Results	YoY
Special Home		COS (Gain on sales of fixed assets)		-6.1	-6.1
Special Items	13.5	SG&A (Restructuring costs in EU)	10.6		-10.6
FY2017 Results	93.2	R&D (Impairment loss)		30.2	+30.2
+		Total	10.6	24.1	+13.5
Positi	ve Factors Negative Factors				7

Profit Attributable to Owners of the Company





Revenue: Major Business Units (incl. Forex Impact)



				()
	FY2016 Q3 YTD Results	FY2017 Q3 YTD Results	YoY	vs. Forecast* (%)
Japan	390.2	418.1	+27.9	78.0%
Daiichi Sankyo Healthcare	51.9	56.6	+4.7	79.7%
Daiichi Sankyo Inc.	115.8	64.1	-51.8	91.5%
Olmesartan	60.9	17.4	-43.6	96.4%
Welchol	32.2	29.3	-2.9	88.7%
Effient	16.5	10.1	-6.4	-
Savaysa	1.4	1.6	+0.2	80.7%
Movantik	2.9	3.7	+0.8	-
Luitpold	64.3	79.9	+15.7	76.1%
Venofer	21.2	24.0	+2.8	77.5%
Injectafer	17.2	25.2	+8.0	72.0%
GE injectables	22.0	28.3	+6.2	-
Daiichi Sankyo Europe	54.4	58.2	+3.8	74.6%
Olmesartan	34.6	25.5	-9.2	79.6%
Efient	6.1	6.0	-0.1	74.6%
Lixiana	6.1	18.5	+12.3	71.1%
ASCA (Asia, South and Central America)	52.5	58.7	+6.2	74.3%
Currency USD/JPY	106.68	111.71	+5.03	* Calculated based of
Rate EUR/JPY	118.09	128.53	+10.44	new forecast update

Revenue: Major Products in Japan



		FY2016 Q3 YTD Results	FY2017 Q3 YTD Results	YoY	vs. Forecast* (%)
Nexium	ulcer treatment	67.4	70.0	+2.5	84.3%
Memary	Alzheimer's disease treatment	36.3	38.1	+1.7	76.1%
Olmetec	antihypertensive agent	54.1	40.5	-13.7	86.1%
Lixiana	anticoagulant	17.9	34.7	+16.8	77.0%
Loxonin	anti-inflammatory analgesic	29.3	29.0	-0.3	80.6%
Tenelia	type 2 diabetes mellitus treatment	19.7	20.9	+1.2	80.3%
Pralia	treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	13.3	17.3	+4.0	75.0%
Rezaltas	antihypertensive agent	13.6	13.1	-0.5	82.2%
Ranmark	treatment for bone complications caused by bone metastases from tumors	10.6	11.7	+1.1	78.1%
Efient	antiplatelet agent	7.8	9.9	+2.1	76.5%
Inavir	anti-influenza treatment	7.9	9.3	+1.4	51.5%
Cravit	synthetic antibacterial agent	12.0	10.1	-1.9	77.6%
Urief	treatment for dysuria	8.9	8.7	-0.2	78.9%
Omnipaque	contrast medium	11.1	11.0	-0.1	84.4%
Mevalotin	antihyperlipidemic agent	8.3	7.0	-1.3	77.8%



FY2017 Revised Consolidated Forecast


FY2017 Revised Consolidated Forecast



			(Bn JPY)	
	FY2017 Forecast (as of Oct.)	FY2017 Forecast (as of Jan.)	vs. Forecast (as of Oct.)	Major factors - Daiichi Sankyo Healthcare (OTC) +2.0 - Daiichi Sankyo Inc. +8.0 - Luitpold +2.0
Revenue	930.0	950.0	+20.0	- Daiichi Sankyo Europe +12.0 - ASCA -5.0
Cost of Sales	337.0	347.0	+10.0	Major factors
SG&A Expenses	297.0	297.0	0.0	 Increased by sales increase (incl. transitory costs)
R&D Expenses	221.0	231.0	+10.0	Major factors
Operating Profit	75.0	75.0	0.0	 Increased by accelerated R&D
Profit before Tax	75.0	75.0	0.0	
Profit attributable to owners of the Company	50.0	50.0	0.0	
Currency Rate EUR/JPY	110.54 123.14	111.28 126.39	Assumption of curr USD/JPY:110, EU	



Edoxaban (Lixiana)



Lixiana : For Maximization of Product Value



Japan

Launched anticoagulant Lixiana OD (Orally Disintegrating)

tablets (Nov. 2017)

Only OD tablets in direct oral anticoagulant (DOAC)

Global HokusaiVTE

Met primary endpoint in Investigational Hokusai-VTE

CANCER Study evaluating edoxaban versus the standard of

care in US/EU dalteparin (injectable) in venous

thromboembolism (VTE) associated with cancer (Dec. 2017)

- The 1st DOAC to show non-inferiority against dalteparin
- Presented as late breaking at ASH 2017




R&D Update

DS-8201: Broad and Bold Program








DS-8201: P1 Study Design



Result of gastric cancer cases from Part 1 and Part 2b was presented



*Subjects in part 1 are not required to have HER2-positive (IHC 3+ or IHC2+/ISH-positive) tumors.

BC, breast cancer; EWOC, escalation with overdose control; FISH, fluorescent in situ hybridization; GC, gastric cancer; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; HNSTD, highest non-severely toxic dose; IHC, immunohistochemistry; ISH, in situ hybridization; IV, intravenous; mCRM, modified continuous reassessment method; NGS, next-generation sequencing; Q3W, once every 3 weeks; RD, recommended dose for dose expansion; T-DM1, trastuzumab emtansine.

DS-8201: Patient Background	ASCO GI 2018 Poster
	Gastric/GEJ Adenocarcinoma (N = 45)
Age (years), median (range) ECOG performance status, n (%) :Score to show limitation of patient's daily living abilities. (5 has most limitation and anticancer drug can be administered below 2)	68.0 (38–79)
0	33 (73.3)
1	12 (26.7)
HER2 expression (IHC), n (%)*	· · · · ·
3+	36 (80.0)
2+	8 (17.8)
ISH positive	7 (15.6)
ISH negative [†]	1 (2.2)
1+	0
Missing	1 (2.2)
Number of prior cancer regimens, n (%)	
1	1 (2.2)
2	15 (33.3)
3	8 (17.8)
4	9 (20.0)
5 or more	12 (26.7)
Prior therapy, n (%)	
CPT-11 (irinotecan)	24 (53.3)
Trastuzumab	44 (97.8)

Analysis set: Enrolled to DS-8201 5.4 and 6.4 mg/kg groups.

*Local laboratory testing; Herceptest Scoring Criteria (CAP/ASCO 2013)- 3+: Uniform intense complete membrane staining in >10% of invasive tumor cells; 2+: Incomplete membrane staining that is weak to moderate in >10% of cells, or intense complete membrane staining in ≤10% of invasive tumor cells; 1+: Faint, incomplete membrane staining in >10% of invasive tumor cells; and 0: No staining is observed in invasive tumor cells or faint incomplete membrane staining in ≤10% of cells.

[†]Negative or examined but not expressing.

ECOG, Eastern Cooperative Oncology Group; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization.

010040

ıkyo

DS-8201: P1 Study Part 1+2b Efficacy





ORR was 45.5% in total evaluable patients

ORR was 43.5% in patients with prior treatment of CPT-11 (irinotecan)

	Gastric / GEJ Adenocarcinoma		
	Total Evaluable (n = 44)	Prior CPT-11* Treated (n = 23)	
ORR, n (%)	20 (45.5)	10 (43.5)	
DCR, n (%)	36 (81.8)	19 (82.6)	
PFS (months), median (95% CI)	5.8 (3.0, 8.3)	4.1 (2.5, 8.3)	
Duration of follow-up (months), median (95% CI)	5.6 (3.7, 7.6)	4.8 (3.0, 7.8)	
Duration of response (months), median (95% CI)	7.0 (NR)	6.9 (NR)	

*CPT-11 is irinotecan.

Analysis set for ORR (CR+PR) and DCR (CR+PR+SD): Efficacy evaluable for confirmed overall response, at least 2 postbaseline scans or PD at the first scan (5.4 and 6.4 mg/kg).

Analysis set for PFS: Efficacy evaluable for PFS, at least one postbaseline scan (5.4 and 6.4 mg/kg). At the time of data cutoff, one subject is on treatment but does not have any post baseline scans.

Minimum and maximum of PFS that includes "+" after value indicates censoring.


CI, confidence interval; CR, complete response; DCR, disease control rate; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; NR, not recorded; ORR, objective response rate; PFS, progression-free survival; PR, partial response; SD, stable disease.

DS-8201: P1 Study Part 1+2b Efficacy

ASCO GI 2018 Poster



17 patients continue treatment




DS-8201: P1 Study Part 1+2b Efficacy ADC





Tumor reductions are continuing in many patients




DS-8201: CT Imaging of PR

ASCO GI 2018 Poster



76 y/o Male gastric cancer with liver mets, IHC3+ (6.4mg/kg)

Pretreatment (August, 2016)



More than 30% tumor shrinkage was observed (PR)

DS-8201: Adverse Events >20% (N=45)





No grade 5 treatment-emergent adverse events

Preferred term*	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	All n (%)
Hematologic					
Anaemia	0	5 (11.1)	11 (24.4)	0	16 (35.6)
Platelet count decreased	6 (13.3)	1 (2.2)	6 (13.3)	2 (4.4)	15 (33.3)
White blood cell count decreased	1 (2.2)	7 (15.6)	5 (11.1)	2 (4.4)	15 (33.3)
Neutrophil count decreased	1 (2.2)	3 (6.7)	7 (15.6)	2 (4.4)	13 (28.9)
Gastrointestinal disorders					
Nausea	29 (64.4)	2 (4.4)	1 (2.2)	0	32 (71.1)
Decreased appetite	18 (40.0)	8 (17.8)	3 (6.7)	0	29 (64.4)
Constipation	12 (26.7)	2 (4.4)	0	0	14 (31.1)
Vomiting	10 (22.2)	0	0	0	10 (22.2)
Diarrhoea	10 (22.2)	0	0	0	10 (22.2)
Others	· · · ·				. ,
Pyrexia	8 (17.8)	2 (4.4)	0	0	10 (22.2)

Analysis set: Safety evaluable, at least one dose of DS-8201a (5.4 and 6.4 mg/kg).

There were no grade 5 treatment-emergent adverse events.

*Coded with MedDRA version 18.0.

GEJ, gastroesophageal junction; MedDRA, Medical Dictionary for Regulatory Activities.

 Three subjects discontinued treatment due to TEAEs (pneumonia, decreased appetite, and pneumonitis)

One case of grade 2 ejection fraction decrease has been reported by the investigators

 Two potential cases of interstitial lung disease (ILD)/pneumonitis were reported by the investigators (one grade 1 and one grade 3), which will be adjudicated by an independent ILD adjudication committee

DS-8201: Conclusions at ASCO GI



- DS-8201 has shown manageable safety and promising antitumor activity in heavily pretreated subjects with HER2-positive gastric cancer who have previously received trastuzumab, regardless of prior CPT-11 treatment
- Promising efficacy and safety of DS-8201, a novel ADC, in HER2-expressing gastric cancer warrants further investigation



DESTINY-Gastric01 study is on-going

- Pivotal phase 2 study
- Examine the efficacy and safety of DS-8201 in HER2-expressing unresectable and/or metastatic gastric cancer who progressed on 2 or more prior regimens (NCT03329690)


DS-8201: Rationale of Neratinib Combo



Research collaboration with Puma and Memorial Sloan Kettering Cancer Center (Dec. 2017)

Test synergetic effect hypothesis in non-clinical study

- HER2 dual blockage by combination of DS-8201 and neratinib
- Increase of internalization rate of DS-8201 by neratinib (increase uptake rate of DS-8201 into tumor)





Appendix

- R&D Milestone Events
- Major R&D Pipeline
- Out-licensing Projects
- Edoxaban (Lixiana)
- Injectafer
- Abbreviations

R&D Milestone Events




Droject	Indication / Study	FY2	FY2017		FY2018		
Project		3 Q	4 Q	Q1	Q2	Q3	
Quizartinib	P3: QuANTUM-R AML2 nd line treatment			TL	_R		
Quizartinip	P1: AML with DS-3032			Study ir	nitiation		
	P2: Pivotal HER2+ Gastric (post trastuzumab)	Study initiation					
	P3: HER2+ Breast Post T-DM1 vs Phys Choice			Study ir	nitiation		
	P3: HER2+ Breast vs T-DM1			Study ir	nitiation		
	P3: HER2 low Breast					Study initiation	
DS-8201	P2: HER2+ CRC		Study initiation				
	P2: HER2+ NSCLC			Study initiation			
	P1b: HER2+ Breast Bladder with nivolumab			Study initiation			
	P1/2: HER2+ Breast NSCLC with IO					Study initiation	
	P1/2: HER2+ Breast Gastric with IO					Study initiation	
U3-1402	P1/2: HER3+ Breast			P2 part Study initiation			
	P1: EGFRm NSCLC		Study initiation				
DS-1062	P1: Solid tumor (NSCLC)		Study initiation				
DS-1205	P1: EGFRm NSCLC with osimertinib		Study initiation				
Hydromorphone	P3: Cancer pain (injection formulation)		<u>Approved</u>				
Mirogabalin	P3: PHN / DPNP		Submission				
Esaxerenone	P3: Essential hypertension		Submission				
DS-5141	P1/2: Duchenne Muscular Dystrophy		ті	.R			

Major R&D Pipeline

As of January 2018





Out-licensing Projects


As of January 2018



	Pre-clinical	Phase1	Phase 2	Phase 3
Oncology		 DS-6051 (NTRK/ROS1 inhibitor) U3-1784 (anti-FGFR4 antibody) DS-1123 (anti-FGFR2 antibody) 		
Specialty Medicine	 DS-1515 (Inflammatory disease/PI3Kō inhibitor) DS-1039 (Cystic fibrosis / new MOA (CFTR independent fluid secretion)) DS-7411 (Hemophilia A and B / antibody) 	DS-2969 (Clostridium difficile infection / GyrB inhibitor)	Laninamivir (CS-8958/Anti-influenza/ Out- licensing with Aviragen)	

Lixiana: Growth in Japan





Copyright © 2018 IQVIA. Calculated based on JPM FY2014 Q1 - FY2017 Q3 Reprinted with permission

Lixiana: Growth in Japan




Lixiana has reached top Rxs share since Mar. 2017 in prescription number of new patients for AF+VTE. The share expanded to **38.4%** in Dec. 2017. 38.4% (Dec. 2017) 40 35 30 25 20 15 10 5 0 N^{α} N^{α

Lixiana : Growth in Germany and South Korea

Daiichi-Sankyo


Steady growth since launch

Reached 3rd share in Germany and South Korea



Growth of Injectafer





Source: IMS National Sales Perspectives NOV 2017 (includes all US IV Iron sales in all channels including dialysis chains)

33

Abbreviations



Abbreviation	
BTD	Breakthrough therapy designation
CR	Complete response
DCR	Disease control rate
DLT	Dose limiting toxicity
DOR	Duration of response
EGFR	Epidermal growth factor receptor
MTD	Maximum tolerated dose
NSCLC	Non-small-cell lung cancer
ORR	Overall response rate Objective response rate
OS	Overall survival
PD	Progress disease
PFS	Progression-free survival
PR	Partial response

Contact address regarding this material

Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: DaiichiSankyoIR@daiichisankyo.co.jp